SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001104659-22-112946
Filing Date
2022-10-31
Accepted
2022-10-31 16:00:59
Documents
2
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm2225498d1_sc13ga.htm SC 13G/A 50479
2 EXHIBIT 99.2 tm2225498d1_ex99-2.htm EX-99.2 19888
  Complete submission text file 0001104659-22-112946.txt   71943
Mailing Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Business Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 (617) 871-8000
Novartis Institutes for BioMedical Research, Inc. (Filed by) CIK: 0001673852 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Subject) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91506 | Film No.: 221345936
SIC: 2836 Biological Products, (No Diagnostic Substances)